We are pleased to share the poster recently presented at ESMO – European Society for Medical Oncology Congress 2022.
FIRST-IN-HUMAN, DOSE ESCALATION PHASE I TRIAL OF INTRATUMORAL CYPEP-1 IN PATIENTS WITH ADVANCED SOLID TUMORS
Eskens et al. Annals of Oncology, Volume 33, S758, 476P
Administration of CyPep-1 is well tolerated. Both molecular and clinical findings suggest strong biologic activity.